P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …

Carbapenem resistance in Gram-negative bacteria has come into sight as a serious global
threat. Carbapenem-resistant Gram-negative pathogens and their main representatives …

Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …

ABSTRACT Imipenem (IMI)/cilastatin/relebactam (REL)(I/R) is a novel β-lactam/β-lactamase
inhibitor combination with expanded microbiologic activity against carbapenem-resistant …

ABSTRACT Introduction Carbapenem-resistant (CR) Pseudomonas aeruginosa infections
constitute a serious clinical threat globally. Patients are often critically ill and/or …

Gram-negative bacterial resistance to antimicrobials has had an exponential increase at a
global level during the last decades and represent an everyday challenge, especially for the …

Introduction Novel last resort beta-lactam antibiotics are now available for management of
infections due to New-Delhi Metallo-Beta-Lactamase (NDM) producing Enterobacterales …

Antimicrobial resistance represents a serious threat for global health, causing an
unacceptable burden in terms of morbidity, mortality and healthcare costs. In particular, in …

Severe infections caused by DTR-GNB pose a formidable challenge for healthcare
providers and represent a growing global health issue. The proper administration and …

With the current crisis related to the emergence of carbapenem-resistant Gram-negative
bacteria (CR-GNB), classical treatment approaches with so-called “old-fashion antibiotics” …